News from mind cure health inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 17, 2021, 03:30 ET MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression

MINDCURE will distribute these protocols to therapists through iSTRYM, its digital therapeutics platform. This milestone in protocol development...

Jun 03, 2021, 03:30 ET MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

By manufacturing ibogaine, MINDCURE's research team will have access to a predictable and standardized supply of synthetic ibogaine while ensuring...

May 20, 2021, 03:30 ET Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer

Dr. Raskin is a psychiatrist and academic with 20 years of international pharmaceutical experience in neuroscience drug development, lifecycle...

May 19, 2021, 03:30 ET MINDCURE Appoints Dr. John Brownstein, the Chief Innovation Officer at Boston Children's Hospital, as Company Advisor

Dr. Brownstein, an esteemed epidemiologist, researcher at Boston Children's Hospital and professor at Harvard Medical School, will assist on...

Apr 27, 2021, 07:45 ET MINDCURE Announces Partnership with SOMA Breath Inc. to License its Breathwork Program and Develop Custom Breathwork for Psychedelic-Assisted Psychotherapies within iSTRYM

Breathwork has shown promise at both replicating the experience of psychedelics and helping patients to integrate psychedelic-assisted psychotherapy...

Apr 22, 2021, 08:45 ET MINDCURE Announces Experienced Finance Executive Michael Wolfe as CFO and appoints Larissa Chaikowsky to its Board of Directors

Mr. Wolfe has extensive capital markets and debt and equity financing experience; Ms. Chaikowsky, the COO at BMO Wealth Management, has significant...

Apr 21, 2021, 08:45 ET MINDCURE Partners its iSTRYM Technology with LUCID to Discover and Create Proprietary Music Experiences for Use During Psychedelic-Assisted Therapy Sessions

LUCID's technology platform unites music, AI and research in neuroscience to create personalized digital music therapy managed in real-time by...

Apr 14, 2021, 03:30 ET MINDCURE Announces The Addition of Daniel Herrera, A Pharmaceutical Industry Executive With Specific Experience in Medical Psychoactive Segment

Mr. Herrera, Who Will Join The Company As Its Vice President Of Growth And Strategic Partnerships, Has 15+ Years Of Global Life Sciences Experience...

Apr 13, 2021, 03:30 ET MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company's Psychedelic Digital Therapeutics Technology Platform

Utilizing Speak Ai's technology, iSTRYM will provide Ai-driven intelligence to help therapists identify the most efficient and efficacious outcomes...

Apr 08, 2021, 03:30 ET MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors

ATMA Was The First Private Sector Service Provider In Canada Conducting Legal Psychedelic-Assisted Therapy For A Palliative Care Patient Under The...

Mar 31, 2021, 07:45 ET MINDCURE Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital Therapeutics (DTx) SaaS Platform, Designed To Enhance Effectiveness Of Psychedelic-Assisted Therapies For Practitioners And Patients

Company Now Is In Two High Growth Rate Global Markets With iSTRYM In The DTx Market, Projected To Reach $56 Billion By 2025 And The Global...

Mar 19, 2021, 07:45 ET Ty Tashiro joins MINDCURE as the Senior Translational and Psychometric Architect for iSTRYM's AI-Driven Psychedelic Digital Therapeutic Technology

The award-winning professor and psychology Ph.D. is an expert in translating psychological research and science into Artificial Intelligence backed...

Mar 15, 2021, 07:45 ET MINDCURE Names Tarik Lebbadi as Chief Operating Officer

An accomplished international operator, Mr. Lebbadi led the medical division for Johnson & Johnson and has successfully scaled several high-growth...

Mar 09, 2021, 03:30 ET MINDCURE Receives Unconditional Ethics Approval for its Psychedelic Integration Protocol Research Study

This approval is a key step forward in the development of the company's iSTRYM digital therapeutics platform VANCOUVER, BC, March 9, 2021...

Mar 04, 2021, 03:30 ET MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury

This potential treatment opportunity was confirmed by the company's bioinformatics platform, PsyCollage VANCOUVER, BC, March 4, 2021 /PRNewswire/ -...

Mar 03, 2021, 03:30 ET MINDCURE Announces Manufacturing of Synthetic Ibogaine to be Used in Company's Clinical Research

The Company expects to have ibogaine manufactured and in use for research by Q4. VANCOUVER, BC, March 3, 2021 /PRNewswire/ - Mind Cure Health Inc....

Mar 02, 2021, 03:30 ET MINDCURE Completes Its Initial Strategic Equity Investment in ATMA, Canada's First Commercial Provider of Legal, Psychedelic-Assisted, Therapy Utilizing Psilocybin

The completed equity investment strengthens ties between MINDCURE and ATMA VANCOUVER, BC, March 2, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE:...

Feb 22, 2021, 03:30 ET Mind Cure Announces Addition of Global Technology Leader Robert C. Hill to Board of Directors

The appointment further strengthens the Company's leadership position in the use of technology to develop psychedelic-related treatments VANCOUVER,...

Feb 18, 2021, 03:30 ET MINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform

MINDCURE's first items in a line of original supplements, including Reishi Energy, Lion's Mane Focus, Turkey Tail Immunity, and Teen, available for...

Feb 17, 2021, 19:48 ET Mind Cure Comments on Recent Promotional Activity

VANCOUVER, BC, Feb. 17, 2021 /PRNewswire/ - Mind Cure Health Inc. ("Mind Cure" or the "Company") (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) has been asked ...

Feb 17, 2021, 03:30 ET Mind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics

Celebrated neurologist, psychiatrist and plant-medicine expert Dr. Dan Engle brings years of understanding of psychedelic medicine into research with ...

Feb 16, 2021, 03:30 ET MINDCURE's Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization

MINDCURE's PsyCollage tool to drive decision-making for drug lead optimization and assist in the discovery of target receptors. VANCOUVER, BC, Feb....

Jan 21, 2021, 12:50 ET MINDCURE Included in First Psychedelic ETF & North American Psychedelics Index

Mind Cure among respected life science and therapeutic technology peers in first ever Psychedelic ETF & North American Psychedelic Index VANCOUVER,...

Jan 12, 2021, 03:30 ET Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy

The strategic partnership between Mind Cure and ATMA will bridge access to research locations for psychedelic drug research while providing patient...

Jan 06, 2021, 03:30 ET Mind Cure Announces Build-Out of Digital Therapeutics, iSTRYM: A Technology Platform for Mental Wellness Optimization & Psychedelic Research

Mind Cure's iSTRYM (pronounced eye-stream) has been designed to warehouse the largest collection of psychedelic research and ongoing mental...